In human cancer treatment, immunotherapy has gained attention partially due to the success in some agents targeting immune checkpoint molecules such as programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4)5, 6. This evidence concerns the gene CTLA4 and cancer.